UBS Group
AUTL

UBS Group’s Autolus Therapeutics AUTL Stock Holding History

UBS Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.43M Buy
1,516,991
+211,212
+16% +$331K ﹤0.01% 4940
2026
Q1 		$1.8M Buy
1,305,779
+428,679
+49% +$651K ﹤0.01% 5067
2025
Q4 		$1.75M Buy
877,100
+466,438
+114% +$717K ﹤0.01% 5092
2025
Q3 		$669K Buy
410,662
+56,995
+16% +$111K ﹤0.01% 5883
2025
Q2 		$806K Buy
353,667
+37,440
+12% +$61.9K ﹤0.01% 5622
2025
Q1 		$490K Buy
316,227
+115,995
+58% +$235K ﹤0.01% 5859
2024
Q4 		$471K Buy
200,232
+43,254
+28% +$146K ﹤0.01% 5891
2024
Q3 		$570K Buy
156,978
+21,187
+16% +$84.5K ﹤0.01% 5129
2024
Q2 		$473K Buy
135,791
+42,943
+46% +$185K ﹤0.01% 5042
2024
Q1 		$592K Buy
92,848
+8,193
+10% +$51.1K ﹤0.01% 5064
2023
Q4 		$545K Buy
84,655
+2,345
+3% +$8.94K ﹤0.01% 5041
2023
Q3 		$192K Buy
82,310
+12,217
+17% +$34.8K ﹤0.01% 5400
2023
Q2 		$167K Buy
70,093
+5,726
+9% +$13.6K ﹤0.01% 5607
2023
Q1 		$118K Buy
64,367
+47,368
+279% +$92.6K ﹤0.01% 5789
2022
Q4 		$32.3K Sell
16,999
-24,776
-59% -$62.6K ﹤0.01% 7160
2022
Q3 		$89K Sell
41,775
-298
-0.7% -$883 ﹤0.01% 5802
2022
Q2 		$118K Sell
42,073
-31,785
-43% -$96.7K ﹤0.01% 5295
2022
Q1 		$308K Buy
73,858
+64,808
+716% +$273K ﹤0.01% 5037
2021
Q4 		$47K Buy
9,050
+1,555
+21% +$9.33K ﹤0.01% 6957
2021
Q3 		$49K Sell
7,495
-8,586
-53% -$54.2K ﹤0.01% 6343
2021
Q2 		$107K Sell
16,081
-2,633
-14% -$16.3K ﹤0.01% 5826
2021
Q1 		$107K Buy
18,714
+13,170
+238% +$97.5K ﹤0.01% 5910
2020
Q4 		$50K Buy
5,544
+2,285
+70% +$24.4K ﹤0.01% 6178
2020
Q3 		$38K Sell
3,259
-1,639
-33% -$23.8K ﹤0.01% 5830
2020
Q2 		$79K Buy
4,898
+1,665
+52% +$18.5K ﹤0.01% 5489
2020
Q1 		$19K Hold
3,233
– – ﹤0.01% 6521
2019
Q4 		$43K Sell
3,233
-2
-0.1% -$26 ﹤0.01% 6430
2019
Q3 		$40K Sell
3,235
-3
-0.1% -$40 ﹤0.01% 6318
2019
Q2 		$52K Buy
+3,238
New +$72.4K ﹤0.01% 5887
2019
Q1 		– Sell
-884
Closed -$29K – 7717
2018
Q4 		$29K Buy
884
+808
+1,063% +$26.6K ﹤0.01% 6499
2018
Q3 		$2K Sell
76
-216
-74% -$5.83K ﹤0.01% 7727
2018
Q2 		$8K Buy
+292
New +$7.72K ﹤0.01% 7249

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group's AUTL Position: Q2 2026 in Review

UBS Group increased its Autolus Therapeutics (AUTL) stake by 16% in Q2 2026, buying an estimated $331K and bringing the position to 1,516,991 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #4940.

UBS Group first reported a position in AUTL in Q2 2018 and has held it in 32 quarters since. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • UBS Group held 1,516,991 shares of Autolus Therapeutics worth $2.43M as of Q2 2026.
  • UBS Group bought 211,212 Autolus Therapeutics shares in Q2 2026, an estimated $331K.
  • Autolus Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4940 holding.
  • UBS Group first reported a position in Autolus Therapeutics in Q2 2018 and has held it in 32 quarters since.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.